期刊文献+

组蛋白去乙酰化酶抑制剂与人类免疫缺陷病毒再激活 被引量:1

Histone deacetylase inhibitors and reactivation of latent HIV
原文传递
导出
摘要 潜伏的人类免疫缺陷病毒(HIV)可存在于进行抗逆转录病毒治疗的患者的CD4+T细胞中,潜伏状态与前病毒的转录沉默有关,抑制组蛋白去乙酰化酶的活性能再激活部分潜伏的HIV,因此应用HDAC抑制剂并结合抗逆转录病毒治疗的策略为清除潜伏感染细胞的病毒库提供了可能;该综述简述了HIV的潜伏感染及机制、组蛋白去乙酰化酶抑制剂及HDAC抑制剂再激活HIV机制,并进行了总结分析,提示利用HDAC抑制剂该类药物进行这种干扰治疗的方法在治愈HIV感染方面有很好的应用前景。 The latent HIV may exist in the CD4 + T cells of the patients who underwent the antiretroviral therapy, the latent state is associated with the proviral transcriptional silencing, the activity of the inhibition histone deacetylase can reactivate the part of the latent HIV, thus, the use of HDAC inhibitors combineding with antiretroviral therapy can provide possibility of the clearance of viral database in latent infected cells. The review briefly defined the latent HIV infection and the mechanisms of reactivation of HIV of histone deacetylase inhibitors as well as HDAC inhibitors, and it suggests that the use of HDAC inhibitors for such interference therapy has good application prospect for the treatment of HIV infection.
出处 《中华医院感染学杂志》 CAS CSCD 北大核心 2015年第3期718-720,共3页 Chinese Journal of Nosocomiology
基金 河北省科技支撑计划基金项目(132777189) 河北省教育厅青年基金资助项目(QN2014012)
关键词 组蛋白去乙酰化酶抑制剂 抗逆转录病毒 治疗 HIV再激活 Histone deacetylase inhibitor Antiretroviral Therapy Reactivation of HIV
  • 相关文献

参考文献21

  • 1Shirakawa K, Chavez L, Hakre S,et al. Reactivation of latent HIV by histone deacetylase inhibitors[J]. Trends Microbiol, 2013,21(6) ..277-285.
  • 2Taube R,Peterlin M. Lost in transcription: molecular mecha- nisms that control HIV latency[J]. Viruses,2013,5(3):902 927.
  • 3Kent SJ, Reece JC, Petravic J, et al. The search for an HIV cure: tackling Intent infection[J]. The Lancet infectious dis- eases,2013,13(7) :614-621.
  • 4Lehrman G, Hogue IB,Palmer S,et al. Depletion of latent HIV-1 infection in vivo: a proof-of-concept study[J]. The Lancet, 2005, 366(9485) :549-555.
  • 5Dokmanovic M,Clarke C,Marks PA. Histone deacetylase in- hibitors: overview and perspectives[J]. Molecular cancer re- search,2007,5(10) :981-989.
  • 6Martinet N,Bertrand P. Interpreting clinical assays for histone deacetylase inhibitors [J]. Cancer Manag Res, 2011,3: 117- 141.
  • 7Lusic M, Marini B, All H, et al. Proximity to PML Nuclear Bodies Regulates HIV-1 Latency in CD4+ T Cells[J]. CellHost Microbe,2013,13(6)665-677.
  • 8Ott M,Verdin E. Three Rules for HIV Latency: Location, Loca- tion, and Location[J]. Cell Host Microbe, 2013,13(6) : 625- 626.
  • 9Lane AA, Chabner BA. Histone deacetylase inhibitors in cancer therapy[J]. Journal of Clinical Oncolngy, 2009,27 (32) : 5459- 5468.
  • 10Xu W, Parmigiani R, Marks P. Histone deaeetylase inhibitors: molecular mechanisms of action [J]. Oncogene, 2007, 26 ( 37 ) : 5541-5552.

二级参考文献2

同被引文献12

引证文献1

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部